Related Experiment Video
Updated: Jan 24, 2026

Production and Targeting of Monovalent Quantum Dots
Published on: October 23, 2014
Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775
Abstract:
Covalent targeting of EGFR cysteine 797 by osimertinib is one of the most successful breakthroughs in targeted therapy, fundamentally transforming the treatment landscape for non-small cell lung cancer (NSCLC) patients. However, resistance driven by mutation of C797 remains a major clinical challenge. Developing novel covalent strategies beyond C797 targeting presents a compelling opportunity for next-generation EGFR inhibitors. We first demonstrated that cysteine 775, located deep within the ATP-binding pocket, is accessible by a rationally designed covalent molecule ZNL-3, which as the first-in-class covalent cysteine 775 inhibitor exhibited strong efficacy in osimertinib-resistant mouse models. To further enhance resilience to resistance-causing mutations, we developed a dual-warhead, bident compound-YNW-1-which covalently targets both cysteine 775 and 797 simultaneously. YNW-1 is the first intramolecular lock to exhibit balanced reactive efficiency on both cysteines, rendering single-site mutations ineffective to confer resistance. The discovery of ZNL-3 and YNW-1 represents significant advancements in EGFR-targeted drug development, and further optimization toward clinical translation is a worthwhile strategy. SIGNIFICANCE: This study establishes the therapeutic potential of an EGFR covalent inhibitor through unprecedented targeting of cysteine 775 and provides the first demonstration that dual cysteine engagement offers superior efficacy over conventional covalent inhibitors by delaying resistance.
Insights
New covalent inhibitors targeting cysteine 775 and dual cysteine 775/797 engagement offer potent strategies against non-small cell lung cancer (NSCLC) with EGFR mutations, overcoming osimertinib resistance.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Osimertinib's covalent targeting of EGFR cysteine 797 revolutionized non-small cell lung cancer (NSCLC) treatment.
- Resistance mutations, particularly at C797, pose a significant clinical challenge, necessitating next-generation inhibitors.
Purpose of the Study:
- To develop novel covalent strategies targeting alternative sites on EGFR to overcome osimertinib resistance.
- To investigate the efficacy of targeting cysteine 775 and dual targeting of cysteines 775 and 797.
Main Methods:
- Rational design and synthesis of covalent molecules targeting specific EGFR cysteine residues.
- In vitro and in vivo evaluation of novel inhibitors (ZNL-3 and YNW-1) in osimertinib-resistant NSCLC models.
Main Results:
- ZNL-3, a first-in-class covalent inhibitor of EGFR cysteine 775, demonstrated efficacy in osimertinib-resistant models.
- YNW-1, a dual-warhead compound, simultaneously targets both cysteine 775 and 797, showing enhanced resilience to resistance mutations.
- YNW-1 exhibits balanced reactivity, rendering single-site mutations ineffective for resistance development.
Conclusions:
- Targeting EGFR cysteine 775 represents a viable therapeutic strategy for overcoming osimertinib resistance in NSCLC.
- Dual covalent targeting of EGFR cysteines 775 and 797 offers superior efficacy and resistance-delaying properties compared to conventional single-site covalent inhibitors.
- Further optimization of ZNL-3 and YNW-1 holds promise for clinical translation in EGFR-mutated NSCLC.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Resistivity
Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Equivalent Resistance

